A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients with Advanced NSCLC (NCI 10327): Results from Dose Escalation-MedSci.cn

A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients with Advanced NSCLC (NCI 10327): Results from Dose Escalation

Riess, J; Frankel, P; Massarelli, E; Nieva, J; Lai, WCV; Koczywas, M; Shackelford, D; Lanza, I; Reid, JM; Gonsalves, WI; Remick, AJ; Gandara, DR; Piekarz, R; Lara, PN; Newman, E; Villalona-Calero, M; Paik, P

JOURNAL OF THORACIC ONCOLOGY, 2022; 17 (9): S91

科室
- - 订阅+
  - 更多科室
工具
服务